secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0000950170-24-129487
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports positive Phase 1/2a data for [212Pb]VMT-α-NET in NETs; pursuing dose escalation
--------------------------------------------------------------------------------

- No dose-limiting toxicities observed at 2.5 and 5.0 mCi doses; safety profile favorable.
- Eight of nine patients had durable disease control; six of nine had measurable tumor reduction, one confirmed RECIST response.
- Safety Monitoring Committee recommends dose escalation to Cohort 3; company to engage with FDA.
- Plans to file IND for PSV359 (FAP-α targeting) by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017024129487/0000950170-24-129487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017024129487/catx-20241121.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer